Merck Makes Hepatitis C A Priority
This article was originally published in The Pink Sheet Daily
Merck highlighted its hepatitis C franchise at its recent R&D day with analysts and journalists.
You may also be interested in...
Merck and Bristol will run a Phase II trial testing daclatasvir, an NS5A replication complex inhibitor, in tandem with MK-5172, Merck’s potentially pan-genotypic protease inhibitor in a non-exclusive partnership in hepatitis C. It’s the second such deal Bristol has signed this month, following an April 5 agreement with Vertex.
It’s only 2012, but Russia’s Pharma 2020 program hit new highs last month with novel deals from Abbott, J&J, Merck and Pfizer.
With its blockbuster asthma drug Singulair going off-patent at the end of the year, Merck is looking to a few key drugs to fill the revenue gap in the coming years, said the company at a recent Deutsche Bank Healthcare conference.